Quebec, Canada, September 1, 2026
Devonian Health Group Inc. has strengthened the manufacturing and quality-control platform for Thykamine™, its lead pharmaceutical-grade botanical drug candidate, through the independent validation and integration of chemical-composition fingerprinting and biological potency testing. The company announced that validated High-Performance Liquid Chromatography coupled with Mass Spectrometry (HPLC-MS), Nuclear Magnetic Resonance (NMR) spectroscopy, and a validated cell-based biological potency assay using the U937 human cell line have been incorporated into its quality-assurance and quality-control program. The analytical strategy is designed to provide complementary measurements of Thykamine’s chemical composition and biological activity, supporting batch-to-batch consistency and manufacturing reproducibility as the product advances through clinical development. The development is particularly relevant to pharmaceutical quality and CMC because botanical drug products are complex mixtures whose quality cannot always be characterized adequately through conventional chemical testing alone.
Validated HPLC-MS and Biological Potency Testing
Devonian’s enhanced control strategy combines several analytical approaches to characterize Thykamine across different dimensions. The HPLC-MS method provides chemical fingerprinting of the botanical extract, while NMR spectroscopy serves as an orthogonal characterization technique for evaluating overall chemical reproducibility. In parallel, the U937 cell-based assay measures Macrophage Inflammatory Protein-1 beta (MIP-1β) as a biological marker associated with Thykamine’s anti-inflammatory activity. Together, these methods provide both chemical and functional information, allowing Devonian to assess whether independently manufactured batches maintain consistent profiles and biological potency. The HPLC-MS analytical method was independently validated by Chromak Research Inc., while the U937 biological potency assay was independently validated by Pacific BioLabs. Devonian said both methods have been integrated into its Quality Assurance/Quality Program (QA/QP) governing Thykamine extraction, manufacturing and quality control. The two external organizations are also expected to continue performing their respective chemical characterization and biological potency testing on future production batches. This ongoing third-party testing is intended to provide independent verification of chemical consistency and biological activity throughout subsequent manufacturing campaigns.
NMR Data Supports Batch Consistency
Devonian reported that NMR analyses conducted to date have demonstrated greater than 98% reproducibility from batch to batch, providing an additional measure of consistency for the complex botanical extract. Rather than relying on a single analytical method, the company’s manufacturing platform combines chemical fingerprinting, orthogonal structural characterization and biological potency testing. This multilayered approach is particularly important for botanical drug development because the active pharmaceutical material contains multiple chemical constituents that may collectively contribute to biological activity. The company said the analytical framework is intended to strengthen confidence that Thykamine produced in different manufacturing batches meets defined chemical and biological quality standards. For a complex botanical product, establishing reproducibility is an important element of pharmaceutical development and manufacturing control, particularly as a candidate progresses toward additional clinical studies and potential regulatory submissions. Devonian described the validation and integration of these methods as another step toward establishing a pharmaceutical-grade manufacturing platform capable of supporting its expanding development programs.
Advertisement
Botanical Drug Quality Strategy Supports Development
The manufacturing development addresses a fundamental challenge associated with botanical pharmaceuticals. Unlike conventional drugs based on a single defined active molecule, botanical products generally contain complex mixtures of chemical constituents, and their biological effects may arise from the contribution or interaction of multiple components. The U.S. FDA’s Botanical Drug Development Guidance recognizes the need for appropriate chemical characterization and notes that chemical testing alone may not always be sufficient to establish product quality and therapeutic consistency. Where appropriate, the guidance supports the inclusion of a biological assay that reflects the drug’s known or intended mechanism of action. Thykamine is the first pharmaceutical product developed from Devonian’s SUPREX™ platform, a proprietary extraction and manufacturing technology. The company is investigating Thykamine for inflammatory and fibro-inflammatory conditions, including ulcerative colitis, atopic dermatitis, psoriasis and rheumatoid arthritis, with previously reported development including Phase II studies in ulcerative colitis and atopic dermatitis. Devonian describes Thykamine as having anti-inflammatory, antioxidant, immunomodulatory and anti-fibrotic properties. For the pharmaceutical manufacturing sector, the latest development illustrates how validated analytical methods, biological potency assays, third-party testing and quality systems can be integrated into the control strategy for complex drug substances. As Thykamine advances through clinical development, the strengthened manufacturing platform could provide supporting evidence for future CMC development, regulatory submissions and pharmaceutical quality assessment, although the reported validation work does not itself constitute regulatory approval of Thykamine.
Source: Devonian Health Group press release
